Management of Congestion and Diuretic Resistance in Heart Failure
نویسندگان
چکیده
منابع مشابه
Mechanisms and management of diuretic resistance in congestive heart failure.
Diuretic drugs are used almost universally in patients with congestive heart failure, most frequently the potent loop diuretics. Despite their unproven effect on survival, their indisputable efficacy in relieving congestive symptoms makes them first line therapy for most patients. In the treatment of more advanced stages of heart failure diuretics may fail to control salt and water retention de...
متن کاملHypochloremia and Diuretic Resistance in Heart Failure
The fundamental role of sodium in maintenance of fluid homeostasis and progression of heart failure (HF) has been a central paradigm in medicine for more than a century. As a result, a core treatment principal in HF management has been the avoidance of dietary sodium. However, accumulating evidence ranging from the basic sciences to epidemiological studies has challenged this paradigm, suggesti...
متن کاملtolvaptan: a novel diuretic in heart failure management
heart failure (hf) is still a major problem worldwide with high morbidity and mortality rates. the recently developed medication for hf is still incapable of reducing its morbidity and mortality, and clinical data supporting the efficacy and safety of its mainstay therapy remain insufficient. arginine-vasopressin (avp) plays important roles in circulatory and water homeostasis, one of which is ...
متن کاملDiuretic therapy and diuretic resistance in cardiac failure.
s 40 venous capacitance within a few minutes before any with oedema is defined as a clinical state where the braking phenomenon occurs before the therapeutic measurable increase in urinary output can be seen [1,2]. This rapid haemodynamic improvement is goal is reached. thought to be due to the release of vasodilatory prostaglandins [3]. However, in a study in patients with severe oedema, i.v. ...
متن کاملTolvaptan: A Novel Diuretic in Heart Failure Management
Heart failure (HF) is still a major problem worldwide with high morbidity and mortality rates. The recently developed medication for HF is still incapable of reducing its morbidity and mortality, and clinical data supporting the efficacy and safety of its mainstay therapy remain insufficient. Arginine-vasopressin (AVP) plays important roles in circulatory and water homeostasis, one of which is ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nephrology @ Point of Care
سال: 2016
ISSN: 2059-3007,2059-3007
DOI: 10.5301/pocj.5000200